We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

61 hedge funds and large institutions have $8.05M invested in Galectin Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

25% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 12

3% more funds holding

Funds holding: 59 → 61 (+2)

0.28% more ownership

Funds ownership: 11.69% → 11.97% (+0.28%)

8% less call options, than puts

Call options by funds: $84K | Put options by funds: $91K

29% less capital invested

Capital invested by funds: $11.3M → $8.05M (-$3.26M)

Holders
61
Holders Change
+2
Holders Change %
+3.39%
% of All Funds
0.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
15
Reduced
12
Closed
5
Calls
$84K
Puts
$91K
Net Calls
-$7K
Net Calls Change
-$146K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$87.2K
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$84.3K
3
Jane Street
Jane Street
New York
+$47.2K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$39.5K
5
VF
Virtu Financial
New York
+$35.1K

Top Sellers

Rank Fund Capital Flow
1
CCB
Cutter & Co Brokerage
Missouri
-$53.4K
2
Osaic Holdings
Osaic Holdings
Arizona
-$42.4K
3
STA
Summit Trail Advisors
New York
-$39K
4
WANY
Wealthspire Advisors (New York)
New York
-$28K
5
TSS
Two Sigma Securities
New York
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
51
UBS Group
Switzerland
$6.28K +$7.41K +5,561 New
BC
52
Barrett & Company
Rhode Island
$5.63K – – –
MAM
53
Meeder Asset Management
Ohio
$4.31K -$2.42K -1,818 -32%
GI
54
Gradient Investments
Minnesota
$4.29K – – –
BAM
55
Belpointe Asset Management
Nevada
$1.21K +$1.42K +1,066 New
BCPWM
56
Bradley & Co Private Wealth Management
Florida
$1.13K – – –
GWSA
57
Global Wealth Strategies & Associates
Colorado
$1.13K +$1.33K +1,000 New
MCC
58
Money Concepts Capital
Florida
$1.13K +$1.33K +1,000 New
GRP
59
Global Retirement Partners
California
$396 – – –
SIC
60
Salem Investment Counselors
North Carolina
$189 – – –
STA
61
Summit Trail Advisors
New York
– -$39K -23,855 Closed
WANY
62
Wealthspire Advisors (New York)
New York
– -$28K -17,355 Closed
TSS
63
Two Sigma Securities
New York
– -$22K -13,384 Closed
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
– -$21 -13 Closed
1 2
3

GALT Hedge Fund Activity: Q4 2022 in Review

61 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2022, worth a combined $8.05M — down 29% from $11.3M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new GALT positions and 5 closed out — a net gain of 3 holders — while 15 added to existing stakes and 12 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $87.2K. The largest seller was Cutter & Co Brokerage, cutting an estimated $53.4K.

  • 61 institutional investors held Galectin Therapeutics (GALT) as of Q4 2022, up from 59 in Q3 2022.
  • Funds reported $8.05M of Galectin Therapeutics stock for Q4 2022, down 29% quarter-over-quarter.
  • 8 funds opened new Galectin Therapeutics positions in Q4 2022 and 5 closed out, a net change of +3 holders.
  • The largest Galectin Therapeutics buyer in Q4 2022 was Citadel Advisors, an estimated $87.2K added.
  • The largest Galectin Therapeutics seller in Q4 2022 was Cutter & Co Brokerage, an estimated $53.4K sold.

Based on aggregated 13F filings for Q4 2022.